Study S001380

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02877355
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 55
Start: 2016-08-22
Primary completion: 2017-11-24
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2015-004534-10; OTHER:U1111-1175-5246; NIH:2015

Registered primary outcomes

Area under the semaglutide plasma concentration-time curve [From 0 to 24 hours after the 10th dosing]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022495	Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Meier JJ, Diabetes, obesity & metabolism	2022	Other trial	PMID 34957654 DOI	cites ClinicalTrials.gov:NCT02877355
R0011209	Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Overgaard RV, Clinical pharmacokinetics	2021	Other trial	PMID 33969456 DOI	cites ClinicalTrials.gov:NCT02877355; registry reference DERIVED:33969456
R0048049	1013-P: Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects with Type 2 Diabetes Juris Jendrik Meier, Diabetes	2019	Other trial	DOI	cites ClinicalTrials.gov:NCT02877355